Clinical trials
Esophageal Adenocarcinoma clinical trials
Below are recruiting esophageal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07212491Enrolling by invitation
New ways to detect early esophageal changes in Barrett's esophagus
This study tests a new, less invasive way to detect precancerous changes or early cancer in Barrett's esophagus. It uses a sponge or brush to collect cells from your esophagus during a routine endoscopy, which may help find problems earlier and avoid more invasive procedures.
Scottsdale, ArizonaAges 18–90 - NCT06824363RecruitingEarly Phase 1
Intra-tumor injection study for stomach and esophagus cancer with ARID1a mutation
This trial tests a new approach where immune cells are injected directly into the tumor in people with a specific genetic change (ARID1a mutation) in their stomach or esophagus cancer. It aims to see if this treatment can help when used before any other cancer therapy.
Orange, CaliforniaAges 18 years+ - NCT06340711RecruitingPhase 2
Gene therapy plus Keytruda for advanced stomach or esophageal cancer
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
New York, New YorkAges 18 years+ - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT03161522RecruitingPhase 2
Chemo alone versus with radiation or surgery for limited spread
This study tests whether adding radiation or surgery to chemotherapy can improve outcomes for people whose esophageal or stomach cancer has spread to only a few places. If your cancer is “oligometastatic” (up to 3 spots), the trial helps doctors see which approach gives the best control.
Houston, TexasAges 18–79 - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Jacksonville, FloridaAges 18 years+ - NCT05563766RecruitingPhase 2
Itraconazole added for treatable esophageal cancer before surgery
This study tests whether adding itraconazole (an anti-fungal medicine) to standard chemo-radiation before surgery increases the chance of complete tumor response. It’s for people with esophageal (or GE junction) cancer that can be removed with curative surgery after treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT07544589RecruitingPhase 1
Testing DISP-10 for Advanced Gastrointestinal Cancers
This early-stage trial tests a new experimental therapy called DISP-10 in patients with advanced cancers of the stomach, esophagus, or colon that have spread. The goal is to see if this treatment can help shrink tumors and how safe it is.
Duarte, CaliforniaAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT07309991Recruiting
Oxygen Levels After Esophageal Cancer Surgery and Healing Complications
This study looks at whether low oxygen levels in the blood after esophageal cancer surgery increases the risk of problems with how the surgery heals. By understanding this connection, doctors may be able to better prevent or treat healing complications.
Guangzhou, GuangdongAges 18–80 - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Aurora, ColoradoAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Mobile, AlabamaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT07554521RecruitingPhase 2
Tislelizumab Plus Chemotherapy for Advanced Stomach or Esophageal Cancer
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
Los Angeles, CaliforniaAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT05745857RecruitingPhase 2
Scan for early esophagus cancer using infused antibody dyes
This Phase 2 study uses special drug dyes (bevacizumab and cetuximab, each tagged for imaging) during an esophagus scope to help doctors find very early abnormal cells, like low- or high-grade pre-cancer and superficial cancer. If you qualify, the goal is earlier detection and better targeting during diagnosis and treatment.
Groningen, Provincie GroningenAges 18 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Phoenix, ArizonaAges 18 years+ - NCT06469944RecruitingPhase 1/Phase 2
Study of drug combinations for stomach or esophagus cancer
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
Tucson, ArizonaAges 18 years+ - NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
Tucson, ArizonaAges 18 years+ - NCT07125248Recruiting
One vs. Two Drains After Esophageal Cancer Surgery
This study is for people with esophageal cancer who are having open surgery to remove the esophagus. It compares using one chest drain tube versus two to see which leads to a better recovery.
Peshawar, KhyberpukhtunkhwaAges Any age - NCT06649474Recruiting
Oxaliplatin side effects linked to HMGB1 blood levels
This study checks if a substance called HMGB1 in your blood is linked to nerve damage and liver side effects from the chemotherapy drug oxaliplatin. It is for people with a specific type of stomach or pancreas cancer that can be surgically removed.
Clermont-FerrandAges 18 years+
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophageal adenocarcinoma?
- Yes. Clin2 currently lists 109 recruiting esophageal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophageal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophageal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- Metastatic Esophageal Adenocarcinoma
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Unresectable Esophageal Adenocarcinoma
- Advanced Esophageal Adenocarcinoma
- Esophageal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.